KRAS and neoplasm: Consistent with these recommendations, the American Society for Clinical Pathology (ASCP), Association for Molecular Pathology (AMP), College of American Pathologists (CAP), and the American Society of Clinical Oncology (ASCO) also developed a guideline on molecular biomarkers for CRC that also recommends RAS (KRAS/NRAS) genotyping of tumor tissue in all patients with mCRC [44].